Endoscopic therapy for barrett's esophagus: A review of its emerging role in optimal diagnosis and endoluminal therapy

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1575-1582

  Dunki Jacobs, Erik M ^a   Martin, Robert C G ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CANCER INFILTRATION; CANCER INVASION; DISEASE COURSE; EARLY CANCER; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; HUMAN; INTERMETHOD COMPARISON; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MORBIDITY; MORTALITY; PATIENT SAFETY; PHOTODYNAMIC THERAPY; POSTOPERATIVE PERIOD; PRECANCER; RADIOFREQUENCY ABLATION; RECURRENCE RISK; REVIEW; SURGICAL MORTALITY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; CATHETER ABLATION; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; HUMANS; MUCOUS MEMBRANE; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS;

EID: 84862582771     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2163-8     Document Type: Review

References (54)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142-6. (Pubitemid 40277094)
2. National Cancer Institute. Esophageal cancer. http://www.cancer.gov/ cancertopics/types/esophageal (2011). Accessed 3 Aug 2011.
3. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2): 251-5. (Pubitemid 30489769)
4. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-31. (Pubitemid 41772961)
5. Gilbert EW, Luna RA, Harrison VL, Hunter, JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg. 2011; 15:708-18.
6. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and metaanalysis. Am J Epidemiol. 2008;168(3):237-49. (Pubitemid 352019777)
7. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2006;4(5):566-72. (Pubitemid 44308164)
8. Coleman HG, Bhat S, Murray LJ, et al. Increasing incidence of Barrett's oesophegus: a population-based study. Eur J Epidemiol. 2011;26(9):739-45.
9. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392-9. (Pubitemid 44708937)
10. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103(3):788-97. (Pubitemid 351406009)
11. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med. 1976;295(9):476-80.
12. Chandrasoma PT, Der R, Dalton P, Kobayashi G, Ma Y, Peters J, DeMeester T. Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol. 2001;25(9):1188-93. (Pubitemid 32777719)
13. Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol. 2007;102(6):1154-61. (Pubitemid 46802035)
14. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95(11):3089-96.
15. Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH, Kiyabu M. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg. 1999;230(3):433-8.
16. DeMeester SR. Evaluation and treatment of superficial esophageal cancer. J Gastrointest Surg. 2010;14 Suppl 1:S94-100.
17. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol. 2010;8(9):783-8.
18. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57: 1200-6.
19. Ell C, May A, Pech OL, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007;65(1):3-9.
20. Gan S, Watson DI. New endoscopic and surgical treatment options for early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1478-84.
21. Ginsberg GG. Endoscopic approaches to Barrett's oesophagus with high-grade dysplasia/early mucosal cancer. Best Pract Res Clin Gastroenterol. 2008;22(4):751-72. (Pubitemid 352016346)
22. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy. 2002;34(12):950-5. (Pubitemid 35446323)
23. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's highgrade dysplasia. Gastrointest Endosc. 2007; 66(3):460-8. (Pubitemid 47304412)
24. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003;58(2):183-8. (Pubitemid 38220265)
25. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a metaanalysis and systematic review. Am J Gastroenterol. 2009;104: 502-13.
26. Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut. 2002;51(6):776-80. (Pubitemid 35408594)
27. Ban S, Mino M, Nishioka NS, et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol. 2004;28(11): 1466-73. (Pubitemid 39425513)
28. Yeh RW, Triadafilopoulos G. Endoscopic therapy for Barrett's esophagus. Gastrointest Endosc Clin North Am. 2005;15(3): 377-97. (Pubitemid 40884510)
29. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185-95. (Pubitemid 46157125)
30. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year followup. Gastrointest Endosc. 2008;68:867-76.
31. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10): 781-9.
32. Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc. 2008;68:35-40. (Pubitemid 351902211)
33. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277-88.
34. Shaheen NJ, Overholt BF, Sampliner R, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011;141(2):460-8.
35. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg. 2008;12:1627-37.
36. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: a critical review of surgery. Br J Surg. 1980;67:381-90. (Pubitemid 10059625)
37. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990; 77:845-57. (Pubitemid 20249685)
38. Jamieson GG, Mathew G, Ludemann R, et al. Postoperative mortality following oesophagectomy and problems in reporting its rate. Br J Surg. 2004;91:943-7. (Pubitemid 39070806)
39. Morita M, Nakanoko T, Fujinaka Y, et al. In-hospital mortality after a surgical resection for esophageal cancer: analysis of the associated factors and historical changes. Ann Surg Oncol. 2011;18:1757-65.
40. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;87:1048-55.
41. Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg. 2011;254(1):67-72.
42. Zehetner J, DeMeester SR, Hagen J. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg. 2011; 141(1):39-47.
43. Sepesi B, Watson T, Zhou D, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg. 2010;210(4):418-27.
44. Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278--88.
45. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut. 2003;52: 1081-4. (Pubitemid 36877416)
46. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology. 2011;141(4):1179-1186.
47. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383-7.
48. Gatenby P, Ramus J, Caygill C, et al. Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. Histopathology. 2009;54(7):814-9.
49. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy. 2007;39(7):581-7. (Pubitemid 47098993)
50. Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's Esophagus. Dig Dis Sci. 2010;55:1918-31.
51. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009;136:2101-14.
52. Gondrie JJ, Pouw RE, Sondermeijer CMT, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with highgrade dysplasia: results of the first prospective series of 11 patients. Endoscopy. 2008;40:359-69. (Pubitemid 351696372)
53. Gondrie JJ, Pouw RE, Sondermeijer CMT, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370-79. (Pubitemid 351696373)
54. Sharma VK, Jae Kim H, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy. 2008;40:380-7. (Pubitemid 351696374)